Business Wire

EUNETWORKS

9.9.2021 10:02:12 CEST | Business Wire | Press release

Share
euNetworks Delivers New Critical Internet Infrastructure in the UK and the Netherlands

euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has completed a strategic investment of critical fibre-based internet infrastructure linking London and Amsterdam, including the delivery of a new subsea high fibre count cable system named Scylla that is now in service. This is the first subsea cable system between the UK and the Netherlands since 1999.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210909005383/en/

euNetworks builds and invests in its city and long haul fibre networks to connect the key data centres and data centre hubs across the UK and Europe. The company builds Super Highways on long haul routes that are critical to Europe’s future international bandwidth needs and uses low loss fibre on these routes to deliver a low cost per bit long haul solution for its customers.

This latest state of the art, ultra high capacity fibre system extends euNetworks’ unique Super Highway network onto the Continent after delivering Super Highway 1 linking Dublin and London to Lowestoft in November 2019. euNetworks’ second Super Highway links Lowestoft via the new submarine cable Scylla to IJmuiden and then onto Amsterdam. Combined with euNetworks’ extensive metro networks in Dublin , Manchester , London and Amsterdam , the system enables any data centre to any data centre connectivity between all these metros on euNetworks’ owned and operated fibre, end-to-end.

Detailed design and permitting studies were initiated in August 2019, construction started in April 2020 and services were delivered to customers at the beginning of September 2021. This low loss network is entirely new fibre deployment. The terrestrial backhaul networks utilise new low-loss Corning SMF28 Ultra G657.A1 fibre cables and three entirely new amplification sites for the two cable landings and intermediate repeater in the UK. With existing sites and backhauls built over 20 years ago, these new facilities eliminate the unreliability of old infrastructure and provide scalable and power-efficient amplification housing, with significantly reduced long-run power demands.

Scylla itself is a non-hybrid 96 pair double-armoured sea cable, solely using Corning’s SMF28 ULL (ultra-low loss) G654.C pure silica fibre; giving all customers the benefit of future-proofed ultra-low attenuation on the 211km (cable landing station to cable landing station) unrepeatered system. This low attenuation is critical to achieving lowest cost per bit, directly driving greater bandwidth per fixed-cost transponder.

The North Sea has traditionally been a hostile environment for subsea cables, with a combination of high water current, a mobile sandy seabed and intense fishing presenting regular service challenges due to cable cuts. euNetworks planned and developed Scylla using new technology to both minimise these risks and also to lower the environmental impact from the cable laying process. During planning and mapping, the seabed was modelled to identify sand wave movement together with fishing intensity in areas with historic cable strikes. This highlighted potential areas of risk for the cable lay and subsequent path modification or planned deeper cable burial. euNetworks also used an innovative cable laying technique for telecom cables, utilising a CAPJET trenching system – a high powered water jet more commonly used for power cables – to create the 2-3 metre deep but narrow trench for the cable to lay in. The CAPJET uniquely enables greater precision and ‘micro-routing’ during the cable lay process. The remotely operated system with on-board telemetry allows for steering in real-time. The low ploughing tension allows for quick manoeuvrability, delivering a finer cable lay plan, burial between the troughs in natural sand formations and subsequent deeper burying of the cable over time. This contrasts with a traditional ploughed burial, which may achieve theoretically similar depths, but must follow much straighter paths over sand waves with amplitudes of 8m and pitches of 12o . Such an approach creates risks to the initial lay, uneven burial depth and still leaves the probability of the cable becoming unburied over time. As well as ensuring deeper burial naturally, laying the cable with precision and less impact on the seabed, euNetworks has buried Scylla up to 3 metres deep versus typical 0.7 metres for existing systems, offering better protection against strikes both today and in the future.

On land the company has also designed and planned this new network with sustainability in mind. The route is designed with optimal spacing and attenuation loss between amplifier sites, meaning less ILA/PoP sites compared to other routes in service. The use of modern fibre types plus a reduction in ILA sites along the route meant less construction during deployment, less resources and less power consumption in service. In addition, the technology used within the new ILA sites is new, with more efficient air conditioning monitoring the air being drawn in and hence using less power when cooling. Overall this approach delivers a much lower power consumption per bit and delivers an optimised low carbon footprint network infrastructure.

“This Super Highway is an important investment in Western European bandwidth infrastructure,” said Brady Rafuse, Chief Executive Officer of euNetworks. “We’ve delivered the first new subsea cable on this important route in 20 years and delivered a unique route running between London and Amsterdam to support the many businesses whose connectivity requirements continue to grow. Critically for our customers, this network development continues our approach of delivering highly scalable, owned and operated fibre based sustainable infrastructure to support their needs.”

“We extend our thanks to all those who have worked with us on this project. We look forward to continuing to work closely with our customers in these regions and across our networks, delivering the bandwidth experience and scale they need,” said Rafuse.

About euNetworks

euNetworks is a bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 51 cities in 15 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 450 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye